HC Wainwright Issues Optimistic Outlook for AUTL Earnings

Posted by Brian Himes on Aug 13th, 2026

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Free Report) – Investment analysts at HC Wainwright upped their Q3 2026 earnings estimates for Autolus Therapeutics in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.20) per share for the quarter, up from their previous forecast of ($0.21). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at ($0.21) EPS.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 152.15%. The firm had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million.

Other analysts have also issued reports about the company. Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings lowered Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Finally, Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Get Our Latest Stock Report on Autolus Therapeutics

Autolus Therapeutics Price Performance

AUTL stock opened at $2.12 on Thursday. The company’s 50-day moving average is $1.62 and its 200-day moving average is $1.56. The stock has a market capitalization of $564.26 million, a PE ratio of -2.00 and a beta of 2.07. Autolus Therapeutics has a 1 year low of $1.17 and a 1 year high of $2.43.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its position in shares of Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares in the last quarter. Independent Advisor Alliance bought a new position in Autolus Therapeutics in the 4th quarter valued at about $28,000. Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter valued at about $28,000. Waverly Advisors LLC acquired a new position in Autolus Therapeutics during the 1st quarter valued at about $37,000. Finally, SmartHarvest Portfolios LLC bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $43,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

More Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

Positive Sentiment: Autolus reported second-quarter revenue of $45.69 million, above the $38.56 million analyst consensus, while its adjusted loss of $0.15 per share was narrower than the expected $0.21 loss. Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Positive Sentiment: Management raised its AUCATZYL outlook, signaling stronger-than-anticipated commercial launch momentum. The updated guidance and progress in expanding adoption are the main catalysts supporting investor interest in AUTL. Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
Positive Sentiment: The earnings presentation and conference call highlighted the company’s commercial and operational progress, reinforcing the view that AUCATZYL could become an important source of future revenue. Autolus Therapeutics plc 2026 Q2 Results Earnings Call Presentation
Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the data shows no measurable short position and includes an apparent “NaN” change, it provides little useful insight into current trading pressure.
Negative Sentiment: Despite the quarterly beat, Autolus remains unprofitable, reporting a $0.15 per-share loss, negative return on equity, and a deeply negative net margin. Continued cash needs and execution risks surrounding the AUCATZYL launch may be limiting enthusiasm and contributing to the recent decline.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.